araag2/HINT huggingface dataset:
Clinical trial NCT01360632 (phase 3, status: completed)
Conditions: depressive disorder, depression, depressive disorder, major, mood disorders, mental disorders
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F32.A, F53.0, P91.4, Z13.31, Z13.32, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F34.81, F39, F34.9, F43.21, F10.14, F10.24, F11.14, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8
Drugs: opc-34712 + adt, placebo + adt, placebo + adt
SMILES: O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between 18 and 65 years of age, with diagnosis of major
             depressive disorder, as defined by DSM-IV-TR criteria

          -  The current depressive episode must be equal to or greater than 8 weeks in duration

          -  Subjects must report a history for the current depressive episode of an inadequate
             response to no more than three adequate antidepressant treatments

        Exclusion Criteria:

          -  Females who are breast-feeding and/or who have a positive pregnancy test result prior
             to receiving study drug

          -  Subjects who report an inadequate response to more than three adequate trials of
             antidepressant treatments during current depressive episode at a therapeutic dose for
             an adequate duration

          -  Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic
             or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other
             psychotic disorder, Bipolar I or II disorder

          -  Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of
             borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality
             disorder
Clinical trial NCT01810939 (phase 3, status: completed)
Conditions: chronic kidney disease (ckd), hyperkalemia (hk)
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0, E87.5, P74.31
Drugs: patiromer, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females ages 18 - 80

          -  Chronic kidney disease (CKD) - eGFR 15 to < 60 mL/min/1.73m2 at screening

          -  Hyperkalemia, defined as a serum potassium value of 5.1 to < 6.5 mEq/L at screening

          -  Taking either an Angiotensin-Converting Enzyme (ACE) Inhibitor, an Angiotensin II
             receptor blocker (ARB), or an aldosterone antagonist (AA) medication

          -  Informed consent given

        Exclusion Criteria:

          -  Participants with auto-immune related chronic kidney disease such as lupus nephritis
             or renal scleroderma/scleroderma renal crisis, or mixed connective tissue disease with
             renal involvement

          -  Participants with uncontrolled Type 1 diabetes, defined as or a HbA1c > 10.0 %, or
             hospitalization to treat hyper- or hypo-glycemia in the past 3 months within the
             previous 6 months in participants with Type 2 diabetes

          -  Participants with severe heart failure, defined as NYHA (New York Heart Association)
             class IV

          -  Participants with major surgery including thoracic and cardiac, in the past 3 months,
             or participants with heart or kidney transplant

          -  Participants with significant cardiovascular or cerebrovascular events in the past 2
             months, such as cardiac arrest, myocardial infarction, or stroke

          -  Participants with BMI ≥ 40 kg/m2
Clinical trial NCT00041275 (phase 3, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: megestrol acetate
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of hepatocellular carcinoma (HCC)

               -  Histologically confirmed OR

               -  Meets 2 of the following criteria:

                    -  Radiological evidence of HCC on CT scan, MRI, or ultrasound

                    -  Serum alpha-fetoprotein level at least 400 µg/L

                    -  Positive lipiodol retention

          -  Not amenable to surgery

        PATIENT CHARACTERISTICS:

        Age:

          -  20 to 100

        Performance status:

          -  ECOG 0-3

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 5.8 mg/dL

        Renal:

          -  Creatinine less than 1.7 mg/dL

        Other:

          -  Not pregnant

          -  No clinical encephalopathy

          -  No other malignancy within the past 5 years

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemoembolization for HCC

          -  No prior systemic chemotherapy for HCC

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics

          -  No prior surgery for HCC

        Other:

          -  No prior percutaneous injection for HCC
Clinical trial NCT01043666 (phase 3, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: ym178, placebo, tolterodine er
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with symptoms of overactive bladder for at least 12 weeks before the study

          -  Subjects capable of walking to the lavatory without assistance and measuring the urine
             volume by him/herself

          -  Subject with an average frequency of micturition of 8 or more times per 24-hour period

          -  Subject with an average episode of urgency or urge incontinence of one or more times
             per 24-hours period

          -  Subject having provided written informed consent by him/herself

        Exclusion Criteria:

          -  Subject having stress urinary incontinence as a predominant symptom

          -  Subject with transient symptoms suspected for overactive bladder

          -  Subject complicated with urinary tract infection, urinary stones, and/or interstitial
             cystitis or with a historical condition of recurrent urinary tract infection

          -  Subject complicated with bladder tumor/prostatic tumor or with the historical
             condition

          -  Subject confirmed to have a post-void residual volume of >=100ml or with a clinically
             significant lower urinary tract obstructive disease

          -  Subject with indwelling catheter or practicing intermittent self-catheterization

          -  Subject giving radiotherapy influencing urinary tract functions, or thermotherapy for
             benign prostatic hyperplasia

          -  Subject giving surgical therapy which may influence urinary tract functions within 24
             weeks before the study

          -  Subject with uncontrolled hypertension (indicated by sitting SBP >=180mmHg or DPB >=
             110mmHg)

          -  Subject with a pulse rate >= 110bpm or <50 bpm
Clinical trial NCT00722371 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, pioglitazone hydrochloride, matching placebo to sitagliptin, matching placebo to pioglitazone, metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is highly unlikely to conceive

          -  Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA)
             therapies, or is non-naïve based upon the patient's current diet, medical regimen and
             screening A1c patient is currently not on AHA with a screening A1c >=7.5 % and =<11.0
             % patient is currently on either metformin pr sulfonylurea monotherapy with a
             screening A1c >=7.0 % and =<9.0 %

        Exclusion Criteria

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has
             C=peptide value of =<0.8 ng/mL

          -  Patient has previously been treated with insulin, thiazolidinedione (TZD)
             (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor
             (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a
             clinical study with any DPP-4 inhibitor or incretin mimetic

          -  Patient is on a weight loss program and is not in the maintenance phase or has started
             a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks

          -  Patient has undergone surgery within the prior 30 days or has major surgery planned
             during the study

          -  Patient has a medical history of active liver disease including chronic active
             hepatitis B or C or symptomatic gallbladder disease including primary biliary
             cirrhosis

          -  Patient has received treatment with an investigational product within 12 weeks prior
             to Visit 1
Clinical trial NCT00027300 (phase 3, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: natalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MS, as defined by McDonald et al., criteria # 1-4 (McDonald et al., 2001)

          -  Between the ages of 18 and 50, inclusive.

          -  Baseline EDSS score between 0.0 and 5.0, inclusive.

          -  Have experienced at least one relapse within the 12 months prior to randomization.

          -  Cranial MRI scan demonstrating lesion(s) consistent with MS.

          -  Have given written informed consent to participate in the study.

        Exclusion Criteria:

          -  Primary progressive, secondary progressive, or progressive relapsing MS.

          -  MS relapse has occurred,in the opinion of the investigator, within 50 days prior to
             randomization and/or the subject has not stabilized from a previous relapse.

          -  A clinically significant infectious illness within 30 days prior to randomization.

          -  History of, or abnormal laboratory results indicative of any significant cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             gastrointestinal, dermatologic, psychiatric, renal and/or other major disease, that in
             the opinion of the investigator, would preclude the administration of a recombinant
             humanized antibody immunomodulating agent for 116 weeks.

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

          -  Unable to perform the Timed 25-foot Walk, 9HPT, and PASAT 3.

          -  Abnormal blood tests performed at the Screening Visit.
Clinical trial NCT00665366 (phase 3, status: completed)
Conditions: bipolar disorder mania
ICD codes: F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5
Drugs: aripiprazole, placebo, lithium, valproate
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Li+], CCCC(CCC)C(O)=O
Eligibility criteria:

        Key inclusion criteria:

          -  Clinical diagnosis of bipolar I disorder mania, manic or mixed episode, with or
             without psychotic features

          -  Current ongoing lithium or valproate treatment with the possibility of benefiting,
             based on the investigator's clinical judgment, from adjunctive treatment with
             aripiprazole

          -  Therapeutic serum levels of lithium or valproate and a Young Mania Rating Total Score
             of 16 or higher at screening and baseline

          -  Participants taking current lithium or valproate treatment combined with antipsychotic
             medication other than aripiprazole are acceptable, provided that the other
             antipsychotic medication is washed out at least 3 days prior to the blood draw for
             therapeutic plasma levels of lithium and valproate determination. Long-acting
             antipsychotics must be washed out prior to entering the double-blind treatment.

        Key exclusion criteria:

          -  Women of childbearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period and for up to 4 weeks after the
             last dose of investigational product

          -  A diagnosis of delirium, dementia, amnesia or other cognitive disorder, or a psychotic
             disorder

          -  Current diagnosis of delirium, dementia, a cognitive disorder (ie, amnesia), or a
             psychotic disorder (ie, schizophrenia or schizoaffective disorder)

          -  Current diagnosis of bipolar II disorder, bipolar disorder not otherwise specified, or
             any other primary psychiatric disorder other than bipolar I disorder mania

          -  Thyroid pathology

          -  Demonstrated cocaine abuse or dependence within the past 3 months prior to screening.

          -  History of neuroleptic malignant syndrome from antipsychotic agents

          -  Manic symptoms that investigator considers refractory to treatment

          -  Previous nonresponsive (by investigator judgment) to aripiprazole for manic symptoms

          -  Significant risk of suicide based on history, mental status exam, or investigator
             judgment.
Clinical trial NCT00131404 (phase 3, status: terminated)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: taranabant, comparator: placebo
SMILES: C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN(C)C(=N)NC(N)=N
Reason stopped: 
    the overall profile does not support development for obesity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Obese patients with a body mass index between 30 kg/m2 and 43 kg/m2, inclusive (BMI
             between 27 kg/m2 and 43 kg/m2, inclusive for those with obesity-related comorbidities
             including hypertension, dyslipidemia, and sleep apnea

        Exclusion Criteria:

          -  Patients with serious or unstable current or past medical conditions
Clinical trial NCT00730015 (phase 3, status: completed)
Conditions: chronic constipation
ICD codes: K59.04
Drugs: matching placebo, linaclotide
SMILES: CC1=CC(O)=CC(C)=C1Cl, [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has completed a colonoscopy according to the AGA criteria, with no clinically
             significant findings

          -  Patient has successfully completed protocol procedures (with no clinically significant
             findings): physical exam, 12-lead ECG, or clinical laboratory tests

          -  Patient meets protocol criteria for CC: reports < 3 bowel movements per week and
             reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation
             during > 25% of BMs

          -  Patient demonstrates continued chronic constipation through Pretreatment Period

          -  Patient is compliant with IVRS

        Exclusion Criteria:

          -  Patient has history of loose or watery stools

          -  Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that could confound the study assessments
Clinical trial NCT00300118 (phase 3, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: budesonide, mesalazine
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria (main):

          -  Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic
             and histological, or endoscopic and radiological criteria [endoscopy not older than 12
             months or if older, then clinical signs (e.g. pain localization, pain intensity, blood
             in stool) and behaviour (according to Vienna classification) should be unchanged
             compared to former episodes]

          -  Localisation of CD either in terminal ileum, ascending colon or ileocolitis

          -  Active phase of disease (200 < CDAI < 400)

        Exclusion Criteria (main):

          -  Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with
             present symptoms

          -  CD in the rectum currently present

          -  Short bowel syndrome

          -  Septic complications

          -  Baseline stool positive for germs causing bowel disease

          -  Abscess, perforation or active fistulas

          -  Ileostomy or colostomy

          -  Resection of more than 50 cm of the ileum

          -  Bowel surgery within the last 3 months

          -  Immediate surgery required

          -  Clinical signs of stricturing disease

          -  Subileus within the last 6 months

          -  Suspicion of ileus, subileus or corresponding symptomatology

          -  Contra-indications, special warnings and precautions mentioned in SmPC

          -  Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine
             within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs
             have to be used for maintenance of remission only and dosage has to be unchanged
             within the last 3 months before baseline visit and during the study

          -  Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last
             month before baseline visit

          -  Treatment with anti-TNF-a therapy within 6 months before baseline visit

          -  Conventional steroids (iv, po, rectal) within 2 weeks before the study

          -  > 6 mg/d budesonide po or > 3 g/d mesalazine po within 2 weeks before the study

          -  Patients known to be steroid-refractory or steroid-dependent from former CD episodes

          -  Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last
             2 weeks
Clinical trial NCT00680953 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: denosumab, placebo, alendronate sodium hydrate
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Involutional (postmenopausal and senile) osteoporosis with prevalent fragility
             vertebral fractures

        Exclusion Criteria:

          -  Any underlying condition,(other than BMD) that might have resulted in abnormal bone
             metabolism
Clinical trial NCT00645099 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: olanzapine, paliperidone er
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient meets the DSM-IV criteria for schizophrenia

          -  Patient has a PANSS total score at screening of 60 to 100, inclusive

          -  Patient must, in the opinion of the investigator, benefit from treatment with
             paliperidone ER or olanzapine

          -  Patients on lipid-lowering therapy must be on a stable dose for at least 4 weeks for
             statins, niacin, ezetimibe and resins or for at least 12 weeks for fibrates

          -  Female patients must be postmenopausal (for at least 1 year), surgically sterile,
             abstinent, or, if sexually active, be practicing and effective method of birth control
             (e.g. prescription oral contraceptives, contraceptive injections, intrauterine device,
             double-barrier method, contraceptive patch, male partner sterilization) before entry
             and throughout the study

          -  Women of child-bearing potential must have a negative urine pregnancy test at
             screening

          -  Patient is healthy on the basis of a physical examination and vital signs at screening

        Exclusion Criteria:

          -  Patient has previously been treated with paliperidone ER, olanzapine, or clozapine
             within the past 6 months or has never been treated with an antipsychotic before

          -  Treatment with a depot antipsychotic within the past 3 months

          -  Treatment with a mood stabilizer or a recently initiated antidepressant (<= 3 months)

          -  Patient has abnormal fasting plasma glucose (> 126 mg/dL) or fasting triglycerides
             (TG) levels (> 400 mg/dL) at screening

          -  Relevant history of any significant and/or unstable cardiovascular, respiratory,
             neurologic (including seizures or significant cerebrovascular), renal, hepatic,
             endocrine, or immunologic diseases, including recent or present clinically relevant
             laboratory abnormalities (as deemed by the investigator)

          -  History or current symptoms of tardive dyskinesia

          -  History of neuroleptic malignant syndrome

          -  Pregnant or breast-feeding female